Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KNSA

KNSA - Kiniksa Pharmaceuticals Ltd Stock Price, Fair Value and News

$43.26-1.38 (-3.09%)
Market Closed

71/100

KNSA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

71/100

KNSA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$52.41

Target 3M

$44.56

Target 6M

$47.05

KNSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KNSA Price Action

Last 7 days

3.4%

Last 30 days

5.5%

Last 90 days

16.0%

Trailing 12 Months

114.4%

KNSA RSI Chart

KNSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KNSA Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

88.65

Price/Sales (Trailing)

5.32

EV/EBITDA

60.06

Price/Free Cashflow

31.3

KNSA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$52.41

Target 3M

$44.56

Target 6M

$47.05

KNSA Fundamentals

KNSA Revenue

Revenue (TTM)

598.0M

Rev. Growth (Yr)

61.17%

Rev. Growth (Qtr)

15.34%

KNSA Earnings

Earnings (TTM)

35.9M

Earnings Growth (Yr)

245.24%

Earnings Growth (Qtr)

3.38%

KNSA Profitability

EBT Margin

8.13%

Return on Equity

6.71%

Return on Assets

5.04%

Free Cashflow Yield

3.19%

KNSA Investor Care

Shares Dilution (1Y)

3.49%

Diluted EPS (TTM)

0.46

KNSA Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025481.2M529.3M598.0M0
2024301.8M338.9M384.1M423.2M
2023236.3M280.8M248.7M270.3M
202284.0M129.4M174.8M220.2M
202100038.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Kiniksa Pharmaceuticals Ltd

KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
 CEO
 WEBSITEkiniksa.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES220

Kiniksa Pharmaceuticals Ltd Frequently Asked Questions

KNSA is the stock ticker symbol of Kiniksa Pharmaceuticals Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Kiniksa Pharmaceuticals Ltd is 3.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KNSA's fair value in chart for subscribers.

The fair value guage provides a quick view whether KNSA is over valued or under valued. Whether Kiniksa Pharmaceuticals Ltd is cheap or expensive depends on the assumptions which impact Kiniksa Pharmaceuticals Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KNSA.

As of Wed Jan 28 2026, KNSA's PE ratio (Price to Earnings) is 88.65 and Price to Sales (PS) ratio is 5.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KNSA PE ratio will change depending on the future growth rate expectations of investors.